Repligen Corporation Common Stock vs ProShares UltraPro Short QQQ ETF — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while ProShares UltraPro Short QQQ ETF trades at $37.47 (market cap $2.13B). The key difference: Repligen Corporation Common Stock is far larger — about 5.2× ProShares UltraPro Short QQQ ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| RGEN | SQQQ | |
|---|---|---|
Market Cap | $11.14B | $2.13B |
Volume | 1,259,263 | 37,167,173 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $89.43 |
52-Week Low | $102.87 | $31.83 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $11.02B | — |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.98, up 1.04% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, its performance is directly tied to declines in the Nasdaq-100 index. Recent news highlights its use as a hedging tool against tech sector weakness, with articles discussing its potential benefits amid concerns over the AI-fueled tech rally.
The outlook for SQQQ is inherently tied to market sentiment toward the Nasdaq-100. It presents a high-risk, tactical opportunity for investors seeking to profit from or hedge against a downturn in major technology stocks. Key risks include the daily reset mechanism of leveraged ETFs, which can lead to decay in volatile markets, and the potential for rapid losses if the tech rally resumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →